[Postoperative follow-up of gastric adenocarcinoma with neoplastic markers and 18-FDG-PET/TC]

Ann Ital Chir. 2007 Nov-Dec;78(6):481-5.
[Article in Italian]

Abstract

Introduction: The usefulness of tumour markers CEA, CA19.9 and CA72.4 in association with FDG-PET/TC were prospectively evaluated in the post-operative follow-up of gastric cancer patients.

Material and methods: Fifty one consecutive patients were enrolled in a follow-up programme entailing with periodical clinical evaluations, instrumental examinations and tumour markers assay FDG-PET/TC was performed only in cases of suspected recurrence.

Results: Sensitivity of CEA, CA19.9 e CA72.4 during the follow-up period was respectively: 16%, 33.3% e 50%. Overall sensitivity was 66.6%. Specificity was 100% for CEA, 93.3% for CA19.9, 100% for CA72.4, with an overall specificity of 96.2%. FDG-PET/TC had a sensitivity of 100%.

Conclusions: Tumour markers in association with FDG-PET/TC allow an early identification of recurrences after surgery, with the advantage to start chemotherapy or surgical protocols before the tumour has reached an advanced stage.

MeSH terms

  • Adenocarcinoma / immunology
  • Adenocarcinoma / surgery*
  • Aged
  • Aged, 80 and over
  • Antigens, Tumor-Associated, Carbohydrate / blood
  • Biomarkers, Tumor / blood
  • CA-19-9 Antigen / blood
  • Carcinoembryonic Antigen / blood
  • Female
  • Fluorodeoxyglucose F18*
  • Follow-Up Studies
  • Gastrectomy
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / diagnosis
  • Neoplasm Recurrence, Local / diagnostic imaging*
  • Neoplasm Recurrence, Local / immunology
  • Positron-Emission Tomography*
  • Postoperative Period
  • Prospective Studies
  • Radiopharmaceuticals
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Stomach Neoplasms / immunology
  • Stomach Neoplasms / surgery*
  • Tomography, X-Ray Computed

Substances

  • Antigens, Tumor-Associated, Carbohydrate
  • Biomarkers, Tumor
  • CA-19-9 Antigen
  • CA-72-4 antigen
  • Carcinoembryonic Antigen
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18